Irinotecan liposome with capecitabine for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have pancreatic cancer that has spread or cannot be surgically removed and has grown after first-line chemotherapy.
- You have at least one measurable tumor on a scan.
- You are in generally good health (able to do daily activities, with a performance score of 0 to 2).
- Your blood counts, liver, and kidney function are within certain safe limits.
- You are not pregnant, willing to use birth control if needed, and have no other serious health issues like heart problems or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy drugs for people whose pancreatic cancer has progressed after prior irinotecan treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for pancreatic cancer that hasn't spread. It aims to see if the combination can shrink tumors and improve survival with manageable side effects.
This trial tests a combination of three chemotherapy medicines (liposomal irinotecan, oxaliplatin, and tegafur) given after surgery to remove pancreatic cancer. The goal is to see if this treatment helps prevent the cancer from coming back.
This study looks at how well a specific type of chemotherapy called irinotecan hydrochloride liposome works in people with pancreatic cancer. Researchers want to understand its effects in real-world settings, which may help doctors choose the best treatment for patients.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.